Quick Answer
Inmune Bio, Inc. reported Total Revenue of $50.0 thousand for the year ending 2025.
- Inmune Bio, Inc. showed an increase of +257.1% in Total Revenue from 2024 to 2025.
- This data is from Inmune Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $0.00 | Q2 2018: $0.00 | Q1 2019: $0.00 | Q2 2019: $0.00 | Q1 2021: $4.0 thousand | Q3 2021: $14.0 thousand | Q1 2022: $163.0 thousand | Q2 2022: $16.0 thousand | Q3 2022: $98.0 thousand | Q1 2023: $38.0 thousand | Q2 2023: $46.0 thousand | Q3 2023: $43.0 thousand | Q1 2024: $14.0 thousand | Q1 2025: $50.0 thousand.
- Historical annual values: Fiscal year 2025: $50.0 thousand | Fiscal year 2024: $14.0 thousand | Fiscal year 2023: $155.0 thousand | Fiscal year 2022: $374.0 thousand | Fiscal year 2021: $181.0 thousand | Fiscal year 2020: $11.0 thousand | Fiscal year 2018: $0.00 | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: